3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Gastrointestinal
4
Other hematologic neoplasm
3
Dermatologic
2
Sarcoma
1
Plasma cell
1
Other neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Endocrine
1
CNS
1
Breast
1
Conditions
Myelodysplastic Syndromes
1348
Leukemia, Myeloid, Acute
1132
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
713
Leukemia
675
Precursor Cell Lymphoblastic Leukemia-Lymphoma
645
Myeloproliferative Disorders
525
Leukemia, Myelomonocytic, Chronic
424
Lymphoma, Non-Hodgkin
407
Primary Myelofibrosis
384
Multiple Myeloma
369
Leukemia, Lymphocytic, Chronic, B-Cell
367
Hodgkin Disease
348
Leukemia, Myeloid, Chronic-Phase
304
Lymphoma
291
Blast Crisis
256
Leukemia, Myeloid, Accelerated Phase
238
Lymphoma, Mantle-Cell
231
Lymphoma, Follicular
226
Burkitt Lymphoma
224
Polycythemia Vera
222
Lymphoma, Large B-Cell, Diffuse
219
Lymphoma, B-Cell, Marginal Zone
203
Congenital Abnormalities
192
Anemia, Refractory, with Excess of Blasts
187
Lymphoma, Large-Cell, Immunoblastic
182
Myelodysplastic-Myeloproliferative Diseases
175
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
173
Thrombocythemia, Essential
166
Neoplasms, Plasma Cell
161
Hematologic Neoplasms
161
Interventions
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplastic Processes
×
Myeloid
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA